Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Tivozanib (AV-951)
Cat No.
CEI-0065
Description
Tivozanib (AV-951; KRN-951) is able to markedly inhibit VEGFR-1, VEGFR-2, VEGFR-3, c-Kit and PDGFR with IC50 of 0.21, 0.16, 0.24, 1.63 and 1.72 nM.
CAS No.
475108-18-0
Molecular Weight
454.86
Purity
>99%
Storage
2 years at -20 centigrade
Targets
VEGFR-1, VEGFR-2, VEGFR-3, c-Kit, PDGFR
Molecular Formula
C22H19ClN4O5
Chemical Name
1-(2-chloro-4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-3-(5-methylisoxazol-3-yl)urea
Solubility
DSMO 20 mg/mL Water
In vitro
As an orally active, ATP-competitive, small-molecule, quinoline-urea derivative, Tivozanib (AV-951; KRN-951) is able to markedly inhibit VEGFR-1, VEGFR-2, VEGFR-3, c-Kit and PDGFR with IC50 of 0.21, 0.16, 0.24, 1.63 and 1.72 nM, respectively.
In vivo
Tivozanib produced a significant inhibition of tumor growth and angiogenesis in several different xenograft tumor models in athymic rats. In a phase I clinical trial, tivozanib was safe and tolerable when administered at oral doses up to 1.5 mg on a schedule of 4 weeks on, 2 weeks off treatment. Results from a phase II clinical trial in patients with advanced renal cell carcinoma reported an overall response rate of 25.4% and a median progression-free survival of 11.8 months in patients treated with tivozanib as a single agent. In a Phase II Randomized Discontinuation proved that tivozanib was active and well tolerated in patients with advanced RCC and supported additional development of tivozanib in advanced RCC.
Download
Download Datasheet